Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Recommendation of “Buy” from Analysts

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have received an average rating of “Buy” from the ten analysts that are covering the company, Marketbeat reports. Nine research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $12.8889.

Several brokerages have issued reports on CMPX. Raymond James Financial upgraded Compass Therapeutics to an “outperform” rating and set a $9.00 price objective on the stock in a research note on Tuesday, July 1st. D. Boral Capital reissued a “buy” rating and set a $32.00 target price on shares of Compass Therapeutics in a research note on Tuesday, August 12th. Finally, Guggenheim upped their price target on shares of Compass Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, August 12th.

Institutional Trading of Compass Therapeutics

Large investors have recently added to or reduced their stakes in the business. Vontobel Holding Ltd. bought a new stake in Compass Therapeutics during the first quarter worth approximately $57,000. Squarepoint Ops LLC acquired a new position in Compass Therapeutics in the 4th quarter valued at approximately $35,000. Price T Rowe Associates Inc. MD increased its stake in Compass Therapeutics by 31.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company’s stock valued at $69,000 after buying an additional 11,326 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Compass Therapeutics by 25.2% in the 4th quarter. Renaissance Technologies LLC now owns 278,600 shares of the company’s stock valued at $404,000 after purchasing an additional 56,000 shares during the last quarter. Finally, ProShare Advisors LLC lifted its stake in shares of Compass Therapeutics by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 28,722 shares of the company’s stock valued at $42,000 after purchasing an additional 9,451 shares during the last quarter. 68.43% of the stock is currently owned by institutional investors.

Compass Therapeutics Price Performance

CMPX stock opened at $3.49 on Friday. The stock’s 50 day moving average is $2.93 and its two-hundred day moving average is $2.48. The company has a market capitalization of $482.60 million, a PE ratio of -7.76 and a beta of 1.49. Compass Therapeutics has a 52-week low of $1.25 and a 52-week high of $4.08.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). As a group, sell-side analysts anticipate that Compass Therapeutics will post -0.36 EPS for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.